chemoimmunotherapy plus maintenance therapy vs consolidation therapy with bortezomib.
CR rate, PFS, and OS.
p85 expression in pre-treatment tumor biopsies with respect to CR rate, PFS, and OS.
quantitative real-time reverse-transcriptase polymerase chain reaction (RT-PCR).
D1 isoforms in predicting clinical outcome using quantitative real-time RT-PCR.
expression with clinical outcomes such as response, PFS, and OS.
identify genes differentially silenced or over-expressed with disease recurrence.
OUTLINE: This is a multicenter, open-label, randomized study.
leucovorin calcium IV every 6 hours until blood levels of MTX are in a safe range.
day 3 and continuing until blood counts recover.
and those with progressive disease are removed from therapy.
the first course of chemoimmunotherapy.
patients undergo 1-3 leukapheresis procedures for collection of PBSCs on days 22-25.
once daily beginning on day 4 and continuing until blood counts recover.
maintenance therapy or consolidation therapy with bortezomib.
6 months for 3 years, and then annually for 5 years.